Clinical trial · Observational
Breast Cancer Treatment Based on Organ-like Culture
Sensitivity Detection and Drug Resistance Mechanism of Breast Cancer Therapeutic Drugs Based on Organ-like Culture
NCT03925233CI-TRIAL-00038308unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Based on the breast cancer organ platform, this experiment establishes a drug sensitivity test method that is closer to the body tumor in breast cancer, provides a basis for the accurate treatment of breast cancer, and discusses the possible mechanism of breast cancer drug resistance.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Organoids | — | UNRESOLVED | — |
Interventions
Interventions (29)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aidi Injection | Drug | — | UNRESOLVED |
| Anastrozole | Drug | Anastrozole | ALIAS |
| Apatinib mesylate | Drug | — | UNRESOLVED |
| Bevacizumab | Drug | Bevacizumab | ALIAS |
| Capecitabine | Drug | Capecitabine | ALIAS |
| Carboplatin | Drug | Carboplatin | ALIAS |
| Cisplatin | Drug | Cisplatin | ALIAS |
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Doxorubicin Hydrochloride |
Design
Arms and outcomes
Arms (3)
- label
- HER2+ Breast Cancer
- interventionNames
- Drug: Trastuzumab
- Drug: Doxorubicin Hydrochloride
- Drug: Epirubicin hydrochloride
- Drug: Fluorouracil
- Drug: Paclitaxel
- Drug: Gemcitabine
- Drug: Cisplatin
- Drug: Recombinant Human Endostatin
- Drug: Pirarubicin hydrochloride
- Drug: Pyrrolidine
- Drug: Ixabepilone
- Drug: Tamoxifen citrate
- Drug: Vinorelbine tartrate
- Drug: Carboplatin
- Drug: Methotrexate
- Drug: Eribulin mesylate
- Drug: Toremifene citrate
- Drug: Anastrozole
- Drug: Letrozole
- Drug: Exemestane
- Drug: Fulvestrant
- Drug: Olaparib
- Drug: Bevacizumab
- Drug: Apatinib mesylate
- Drug: Pattozumab
- Drug: Capecitabine
- Drug: Ear particles
- Drug: Aidi Injection
- Drug: Cyclophosphamide
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: Patients with breast cancer and the largest tumor diameter ≥ 3cm No previous chemotherapy regimen age 18-65 years old Can obtain the tumor tissue specimens required for culture Heart, liver, kidney and bone marrow hematopoietic function is good Know and sign the informed consent form Exclusion Criteria: Pregnant or lactating women Also suffering from other cancer patients There are serious uncontrolled medical diseases or acute infections Those who are known to be allergic to this study drug or a variety of previous drugs The patient cannot understand the purpose of the study or disagree with the requirements of the study. Other investigators believe that patients who are not suitable for this study group
References
Publications (0)
Data not yet available
No reference posted for this study.